91
89
Growth Score
38 pts
Heat Score
86 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
4297147
Ameliogenix develops immunotherapies and gene therapies targeting complex disorders with an emphasis on cholesterol-lowering treatments.
About the Company
Ameliogenix develops immunotherapies and gene therapies for complex disorders that are traditionally treated with small-molecule drugs. The company focuses on designing biologic agents intended to reduce off-target interactions and improve therapeutic performance. Its current research centers on cardiovascular disease through next-generation
cholesterol-lowering therapies. Ameliogenix is advancing the AGXV Series, a set of modular immunotherapies that aim to enhance cholesterol metabolism by immune system-mediated removal of inhibitory factors. The lead candidate, AGXV1, is in preclinical lab testing with a research partner, while AGXV2 and AGXV3 are in conceptual development.
